Advaxis, is a clinical-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins.
ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA ® Expansion of off-the-shelf ADXS-HOT program with planned Phase 1 study in early prostate cancer with
Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of ADXS-503 to restore and/or enhance sensitivity to checkpoint inhibitors PRINCETON, N.J.
PRINCETON, N.J. , April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination
